20 results on '"Adolfsson, Jan"'
Search Results
2. Drugs for metabolic conditions and prostate cancer death in men on GnRH agonists.
- Author
-
Bosco, Cecilia, Wong, Chloe, Garmo, Hans, Crawley, Danielle, Holmberg, Lars, Hammar, Niklas, Adolfsson, Jan, Stattin, Pär, and Van Hemelrijck, Mieke
- Subjects
PROSTATE cancer treatment ,METABOLIC disorder treatment ,ANTINEOPLASTIC agents ,GONADOTROPIN releasing hormone ,PROPORTIONAL hazards models ,REGRESSION analysis - Abstract
Objective: To evaluate whether drugs for metabolic conditions influence prostate cancer‐specific mortality in men starting gonadotrophin‐releasing hormone (GnRH) agonists, as it is unclear whether metabolic syndrome and its related drugs is affecting treatment response in men with prostate cancer on GnRH agonists. Patients and Methods: We selected all men receiving GnRH agonists as primary treatment in the Prostate Cancer data Base Sweden (PCBaSe) (
n = 9267). Use of drugs for metabolic conditions (i.e. anti‐diabetes, anti‐dyslipidaemia, and antihypertension) in relation to all‐cause, cardiovascular disease (CVD), and prostate cancer‐specific death were studied using multivariate Cox proportional hazard and Fine and Gray competing regression models. Results: In all, 6322 (68%) men used at least one drug for a metabolic condition at GnRH agonist initiation: 46% on antihypertensive drugs only, 32% on drugs for dyslipidaemia and hypertension, and ~10% on drugs for more than two metabolic conditions. Cox models indicated a weak increased risk of prostate cancer death in men who were on drugs for hypertension only (hazard ratio [HR] 1.12, 95% confidence interval [CI] 1.03–1.23) or drugs for hyperglycaemia (HR 1.19, 95% CI 1.06–1.35) at GnRH agonist initiation. However, upon taking into account competing risk from CVD death, none of the drugs for metabolic conditions were associated with an increased risk of prostate cancer death. Conclusion: We did not find evidence for a better or worse response to GnRH agonists in men with prostate cancer who were also on drugs for hypertension, dyslipidaemia, or hyperglycaemia. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
3. Association between type 2 diabetes, curative treatment and survival in men with intermediate‐ and high‐risk localized prostate cancer.
- Author
-
Crawley, Danielle, Garmo, Hans, Rudman, Sarah, Stattin, Pär, Zethelius, Björn, Holmberg, Lars, Adolfsson, Jan, and Van Hemelrijck, Mieke
- Subjects
PROSTATE cancer treatment ,CURATIVE medicine ,TYPE 2 diabetes complications ,PROGRESSION-free survival ,HEALTH outcome assessment - Abstract
Objective: To investigate whether curative prostate cancer (PCa) treatment was received less often by men with both PCa and Type 2 diabetes mellitus (T2DM) as little is known about the influence of T2DM diagnosis on the receipt of such treatment in men with localized PCa. Subjects and Methods: The Prostate Cancer database Sweden (PCBaSe) was used to obtain data on men with T2DM and PCa (
n = 2210) for comparison with data on men with PCa only (n = 23 071). All men had intermediate‐ (T1–2, Gleason score 7 and/or prostate‐specific antigen [PSA] 10–20 ng/mL) or high‐risk (T3 and/or Gleason score 8–10 and/or PSA 20–50 ng/mL) localized PCa diagnosed between 1 January 2006 and 31 December 2014. Multivariate logistic regression was used to calculate the odds ratios (ORs) for receipt of curative treatment in men with and without T2DM. Overall survival, for up to 8 years of follow‐up, was calculated both for men with T2DM only and for men with T2DM and PCa. Results: Men with T2DM were less likely to receive curative treatment for PCa than men without T2DM (OR 0.78, 95% confidence interval 0.69–0.87). The 8‐year overall survival rates were 79% and 33% for men with T2DM and high‐risk PCa who did and did not receive curative treatment, respectively. Conclusions: Men with T2DM were less likely to receive curative treatment for localized intermediate‐ and high‐risk PCa. Men with T2DM and high‐risk PCa who received curative treatment had substantially higher survival times than those who did not. Some of the survival differences represent a selection bias, whereby the healthiest patients received curative treatment. Clinicians should interpret this data carefully and ensure that individual patients with T2DM and PCa are not under‐ nor overtreated. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
4. Cancer Specific Mortality in Men Diagnosed with Prostate Cancer before Age 50 Years: A Nationwide Population Based Study.
- Author
-
Thorstenson, Andreas, Garmo, Hans, Adolfsson, Jan, and Bratt, Ola
- Subjects
DIAGNOSIS ,PROSTATE cancer ,PROSTATE cancer treatment ,CANCER-related mortality ,AGE factors in disease ,CLINICAL trials - Abstract
Purpose We compared clinical characteristics and cancer specific mortality in men diagnosed with prostate cancer before vs after age 50 years. Materials and Methods A total of 919 men 35 to 49 years old and 45,098 men 50 to 66 years old who were diagnosed with prostate cancer between 1998 and 2012 were identified in PCBaSe (Prostate Cancer data Base Sweden). Cancer specific mortality was compared among age groups (35 to 49, 50 to 59, 60 to 63 and 64 to 66 years) with and without adjusting for cancer characteristics, comorbidity and education in a multivariable Cox proportional hazards model. Results Clinical cancer characteristics indicated that most nonmetastatic cancer in men younger than 50 years was detected after prostate specific antigen testing. The proportion of nonmetastatic vs metastatic disease at diagnosis was similar in all age groups. A strong association between younger age and poor prognosis was apparent in men in whom metastatic disease was diagnosed before age 50 to 55 years. The crude and adjusted HRs of cancer specific mortality were 1.41 (95% CI 1.12–1.79) and 1.28 (95% CI 1.01–1.62) in men diagnosed before age 50 and at age 50 to 59 years, respectively. In men with nonmetastatic disease crude cancer specific mortality increased with older age but adjusted cancer specific mortality was similar in all age groups. Conclusions Our findings suggest that an aggressive form of metastatic prostate cancer is particularly common in men younger than 50 to 55 years. Genetic studies and trials of intensified systemic treatment are warranted in this patient group. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
5. Causes of death in men with localized prostate cancer: a nationwide, population-based study.
- Author
-
Van Hemelrijck, Mieke, Folkvaljon, Yasin, Adolfsson, Jan, Akre, Olof, Holmberg, Lars, Garmo, Hans, and Stattin, Pär
- Subjects
PROSTATE cancer treatment ,ENDEMIC diseases ,CAUSES of death ,PROSTATE cancer risk factors ,CARDIOVASCULAR disease related mortality ,DISEASE risk factors - Abstract
Objective To detail the distribution of causes of death from localized prostate cancer ( PCa). Patients and Methods The database PCBase Sweden links the Swedish National Prostate Cancer Register with other nationwide population-based healthcare registers. We selected all 57 187 men diagnosed with localized PCa between 1997 and 2009 and their 114 374 PCa-free control subjects, matched according to age and county of residence. Mortality was calculated using competing risk regression analyses, taking into account PCa risk category, age and Charlson comorbidity index ( CCI). Results In men with low-risk PCa, all-cause mortality was lower compared with that in corresponding PCa-free men: 10-year all-cause mortality was 18% for men diagnosed at age 70 years, with a CCI score of 0, and 21% among corresponding control subjects. Of these cases, 31% died from cardiovascular disease ( CVD) compared with 37% of the corresponding control subjects. For men with low-risk PCa, 10-year PCa-mortality was 0.4, 1 and 3% when diagnosed at age 50, 60 and 70 years, respectively. PCa was the third most common cause of death (18%), after CVD (31%) and other cancers (30%). By contrast, PCa was the most common cause of death in men with intermediate- and high-risk localized PCa. Conclusions Men with low-risk PCa had lower all-cause mortality than PCa-free men because of lower CVD mortality, driven by early detection selection; however, for men with intermediate- or high-risk disease, the rate of PCa death was substantial, irrespective of CCI score, and this was even more pronounced for those diagnosed at age 50 or 60 years. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
6. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.
- Author
-
Grönberg, Henrik, Adolfsson, Jan, Aly, Markus, Nordström, Tobias, Wiklund, Peter, Brandberg, Yvonne, Thompson, James, Wiklund, Fredrik, Lindberg, Johan, Clements, Mark, Egevad, Lars, and Eklund, Martin
- Subjects
- *
DIAGNOSIS , *PROSTATE cancer , *PROSTATE cancer risk factors , *PROSTATE cancer treatment , *DISEASES in men , *PROSTATE-specific antigen , *LONGITUDINAL method , *BIOPSY , *BLOOD coagulation factors , *COMPARATIVE studies , *CYTOKINES , *DECISION making , *GENETIC polymorphisms , *RESEARCH methodology , *MEDICAL cooperation , *MULTIVARIATE analysis , *PHARMACOKINETICS , *PROSTATE tumors , *PROTEINS , *RESEARCH , *RISK assessment , *LOGISTIC regression analysis , *EVALUATION research , *PREDICTIVE tests , *RECEIVER operating characteristic curves , *EARLY detection of cancer , *TUMOR grading ,RESEARCH evaluation - Abstract
Background: The prostate-specific antigen (PSA) test is used to screen for prostate cancer but has a high false-positive rate that translates into unnecessary prostate biopsies and overdiagnosis of low-risk prostate cancers. We aimed to develop and validate a model to identify high-risk prostate cancer (with a Gleason score of at least 7) with better test characteristics than that provided by PSA screening alone.Methods: The Stockholm 3 (STHLM3) study is a prospective, population-based, paired, screen-positive, diagnostic study of men without prostate cancer aged 50-69 years randomly invited by date of birth from the Swedish Population Register kept by the Swedish Tax Agency. Men with prostate cancer at enrolment were excluded from the study. The predefined STHLM3 model (a combination of plasma protein biomarkers [PSA, free PSA, intact PSA, hK2, MSMB, MIC1], genetic polymorphisms [232 SNPs], and clinical variables [age, family, history, previous prostate biopsy, prostate exam]), and PSA concentration were both tested in all participants enrolled. The primary aim was to increase the specificity compared with PSA without decreasing the sensitivity to diagnose high-risk prostate cancer. The primary outcomes were number of detected high-risk cancers (sensitivity) and the number of performed prostate biopsies (specificity). The STHLM3 training cohort was used to train the STHLM3 model, which was prospectively tested in the STHLM3 validation cohort. Logistic regression was used to test for associations between biomarkers and clinical variables and prostate cancer with a Gleason score of at least 7. This study is registered with ISCRTN.com, number ISRCTN84445406.Findings: The STHLM3 model performed significantly better than PSA alone for detection of cancers with a Gleason score of at least 7 (p<0·0001), the area under the curve was 0·56 (95% CI 0·55-0·60) with PSA alone and 0·74 (95% CI 0·72-0·75) with the STHLM3 model. All variables used in the STHLM3 model were significantly associated with prostate cancers with a Gleason score of at least 7 (p<0·05) in a multiple logistic regression model. At the same level of sensitivity as the PSA test using a cutoff of ≥3 ng/mL to diagnose high risk prostate cancer, use of the STHLM3 model could reduce the number of biopsies by 32% (95% CI 24-39) and could avoid 44% (35-54) of benign biopsies.Interpretation: The STHLM3 model could reduce unnecessary biopsies without compromising the ability to diagnose prostate cancer with a Gleason score of at least 7, and could be a step towards personalised risk-based prostate cancer diagnostic programmes.Funding: Stockholm County Council (Stockholms Läns Landsting). [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
7. Quantifying the Evidence for the Risk of Metabolic Syndrome and Its Components following Androgen Deprivation Therapy for Prostate Cancer: A Meta-Analysis.
- Author
-
Bosco, Cecilia, Crawley, Danielle, Adolfsson, Jan, Rudman, Sarah, and Van Hemelrijck, Mieke
- Subjects
METABOLIC syndrome risk factors ,ANDROGEN drugs ,PROSTATE cancer treatment ,META-analysis ,MEDICAL statistics - Abstract
Background: No meta-analysis is yet available for the risk of metabolic syndrome (MetS) following androgen deprivation therapy (ADT) for men with prostate cancer. To summarize the evidence for the link between ADT and MetS or its components quantitatively with a meta-analysis including all studies published to date. Methods: PubMed and Embase were searched using predefined inclusion criteria to perform meta-analyses on the association between metabolic syndrome, hyperglycemia, diabetes, hypertension, dyslipidemia or obesity and androgen deprivation therapy in patients with prostate cancer. Random effects methods were used to estimate pooled relative risks (RRs) and 95% confidence intervals (CI). Results: A total of nine studies was included. There was a positive association between ADT and risk of MetS (RR: 1.75 (95% CI: 1.27–2.41)). Diabetes was the only MetS component present in more than 3 studies, and also showed an increased risk following ADT (RR: 1.36 (95% CI: 1.17–1.58)). Conclusion: This is the first quantitative summary addressing the potential risk of MetS following ADT in men with PCa. The positive RRs indicate that there is a need to further elucidate how type and duration of ADT affect these increased risks of MetS and diabetes as the number of men with PCa treated with ADT is increasing. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
8. Rehospitalization after Radical Prostatectomy in a Nationwide, Population Based Study.
- Author
-
Friðriksson, Jón Öm, Holmberg, Erik, Adolfsson, Jan, Lambe, Mats, Bill-Axelson, Anna, Carlsson, Stefan, Hugosson, Jonas, and Stattin, Pär
- Subjects
DIAGNOSIS ,PROSTATE cancer ,PROSTATE cancer treatment ,PROSTATECTOMY ,PATIENT readmissions ,DISEASE incidence ,POSTOPERATIVE care ,COMORBIDITY - Abstract
Purpose: We investigated hospital readmission frequency during the 90 days after radical prostatectomy and assessed the readmission risk associated with potentially related variables. Materials and Methods: Using the population based, nationwide PCBaSe (Prostate Cancer data Base Sweden) we identified men diagnosed with incident prostate cancer between 2000 and 2011 who underwent radical prostatectomy as primary treatment. We used logistic regression analysis to examine the association of the risk of 90-day postoperative readmission with surgical method, calendar period, tumor risk category, hospital case load and patient characteristics. Results: During 90 postoperative days 2,317 of the 24,122 men (10%) identified were nonelectively readmitted, specifically 10% after retropubic, 9% after robot-assisted and 11% after laparoscopic radical prostatectomy. The range in readmission frequency among hospitals was 0% to 35%. Higher readmission risk was associated with the early calendar period (2009 to 2011 vs 2000 to 2002 OR 0.71, 95% CI 0.61–0.83), greater age (70 or greater vs less than 60 years OR 1.17, 95% CI 1.00–1.36), higher risk category (high vs low OR 1.78, 95% CI 1.57–2.03), high comorbidity (Charlson comorbidity index 3 or greater vs 0 OR 1.77, 95% CI 1.29–2.44) and low hospital surgical volume (150 or greater vs fewer than 30 radical prostatectomies per year OR 0.70, 95% CI 0.60–0.81). Conclusions: Readmission rates after different radical prostatectomy methods were similar, ranging from 9% to 11%, with wide variation among hospitals. Readmission rates can be used as an indicator of perioperative care quality but potential confounders must be adjusted to avoid bias. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
9. Primary cancers before and after prostate cancer diagnosis.
- Author
-
Van Hemelrijck, Mieke, Drevin, Linda, Holmberg, Lars, Garmo, Hans, Adolfsson, Jan, and Stattin, Pär
- Subjects
CANCER of unknown primary origin ,DIAGNOSIS ,PROSTATE cancer ,ETIOLOGY of cancer ,PROSTATE cancer treatment ,COLON cancer ,SKIN cancer ,COMPARATIVE studies - Abstract
BACKGROUND: The occurrence of multiple cancers may indicate common etiology; and, although some studies have investigated the risk of second primary cancers after prostate cancer (PCa), there are no studies on cancers before PCa. METHODS: The PCBaSe Sweden database is based on the National Prostate Cancer Register (NPCR), which covers >96% of PCa cases. The authors estimated the prevalence and cumulative incidence of different cancers before and after PCa diagnosis in 72,613 men according to PCa treatment and disease stage in PCBaSe and their matched comparison cohort of men who were free of PCa. RESULTS: In total, 6829 men were diagnosed with another primary cancer before their PCa diagnosis, including 138 men at the time of PCa diagnosis and 5230 men were diagnosed after PCa diagnosis. Cancer of the bladder or colon and nonmelanoma of the skin were the 3 most frequently observed cancers before and after PCa diagnosis. At the time of PCa diagnosis, the prevalence of these 3 cancers was 1.94% for bladder cancer, 1.08% for colon cancer, and 1.08% for nonmelanoma skin cancer, compared with 1.30%, 0.96%, and 1.03%, respectively, for the matched comparison cohort. Five years after PCa diagnosis, the difference in incidence proportion between PCa men and their comparison cohort was 7‰ (95% CI, 5.6‰-8.5‰), 1.3‰ (0‰-2.6‰), and 1.6‰ (0.6‰-2.6‰) for these 3 cancers, respectively. From a uro-oncologic point of view, it is interesting to note that the prevalence of kidney cancer at the time of PCa diagnosis was 0.42% compared with 0.28% for the matched comparison cohort. CONCLUSIONS: Approximately 17% of all PCa occurred in combination with another primary cancer (before or after PCa diagnosis). Detection bias probably explains part of this observation, but further investigations are required to assess possible underlying mechanisms. Cancer 2012. © 2012 American Cancer Society. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
10. Outcome of Primary Versus Deferred Radical Prostatectomy in the National Prostate Cancer Register of Sweden Follow-Up Study.
- Author
-
Holmström, Benny, Holmberg, Erik, Egevad, Lars, Adolfsson, Jan, Johansson, Jan-Erik, Hugosson, Jonas, and Stattin, Pär
- Subjects
PROSTATECTOMY ,HEALTH outcome assessment ,PROSTATE cancer treatment ,PATHOLOGY ,FOLLOW-up studies (Medicine) ,CANCER radiotherapy ,MEDICAL statistics - Abstract
Purpose: We assessed outcomes in terms of adverse pathology and prostate cancer specific mortality in men who underwent primary or deferred radical prostatectomy. Materials and Methods: In the National Prostate Cancer Register of Sweden Follow-Up Study men 70 years old or younger at diagnosis with localized low to intermediate risk prostate cancer diagnosed from 1997 to 2002 were identified. Outcome in terms of adverse pathology, namely upgrading of Gleason score, positive surgical margins and extraprostatic extension, as well as prostate cancer specific mortality, was assessed in 2,344 men who underwent primary radical prostatectomy and 222 who underwent deferred radical prostatectomy after an initial period of surveillance. Results: Upgrading of Gleason score in surgical specimens vs core biopsies was less frequent after primary (25%) vs deferred radical prostatectomy (38%), p <0.001. There was no significant difference in the percentage of men who underwent primary vs deferred radical prostatectomy for positive surgical margins (33% vs 24%) or extraprostatic extension (27% vs 25%), and there was no difference in any 1 or more of the 3 adverse pathology features (55% vs 56%). After a median followup of 8 years 0.7% of men in the primary radical prostatectomy group and 0.9% in the deferred radical prostatectomy group had died of prostate cancer. Conclusions: There was no significant difference in the presence of any 1 or more adverse pathology features or in prostate cancer specific mortality after primary compared to deferred radical prostatectomy. However, longer followup is needed to conclusively evaluate the role of deferred radical prostatectomy. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
11. Surveillance and Deferred Treatment for Localized Prostate Cancer. Population Based Study in the National Prostate Cancer Register of Sweden.
- Author
-
Stattin, Pär, Holmberg, Erik, Bratt, Ola, Adolfsson, Jan, Johansson, Jan-Erik, and Hugosson, Jonas
- Subjects
PROSTATE cancer treatment ,CANCER risk factors ,COHORT analysis ,PROSTATE-specific antigen ,PUBLIC health surveillance ,HORMONE therapy ,CANCER radiotherapy - Abstract
Purpose: To what extent active surveillance and deferred treatment for localized risk prostate cancer are used is unclear. We assessed the use of surveillance and of deferred treatment in a population based, nationwide cohort in Sweden. Materials and Methods: In the National Prostate Cancer Register of Sweden, with a 98% coverage vs the compulsory Swedish Cancer Registry, we identified 8,304 incident cases of prostate cancer in 1997 to 2002 with age younger than 70 years, clinical local stage T1 or 2, N0 or Nx, M0 or Mx and serum prostate specific antigen less than 20 ng/ml. Data were extracted from medical charts for 7,782 of these men (94%) at a median of 4 years after diagnosis. Results: Primary treatment was surveillance for 2,065 men (26%), radical prostatectomy for 3,722 (48%), radiotherapy for 1,632 (21%) and hormonal treatment for 363 (5%). Men on surveillance had lower local tumor stage, grade and prostate specific antigen, and were older than those who received active primary treatment (p <0.001). After a median surveillance of 4 years 711 men (34%) on surveillance had received deferred treatment, which was radical prostatectomy for 279 (39%), radiotherapy for 212 (30%) and hormonal treatment for 220 (30%). Conclusions: Surveillance was a common treatment for patients younger than 70 years with localized prostate cancer in Sweden in 1997 to 2002, 26% of men with localized prostate cancer started surveillance and after a median followup of 4 years, 66% of these men remained on surveillance. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
12. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005.
- Author
-
Adolfsson, Jan, Garmo, Hans, Varenhorst, Eberhard, Ahlgren, Göran, Ahlstrand, Christer, Andrén, Ove, Bill-Axelson, Anna, Bratt, Ola, Damber, Jan-Erik, Hellström, Karin, Hellström, Magnus, Holmberg, Erik, Holmberg, Lars, Hugosson, Jonas, Johansson, Jan-Erik, Petterson, Bill, Törnblom, Magnus, Widmark, Anders, and Stattin, Pär
- Subjects
- *
PROSTATE cancer treatment , *CANCER treatment , *PROSTATE-specific antigen , *ADENOCARCINOMA - Abstract
Objective. The incidence of prostate cancer is rising rapidly in Sweden and there is a need to better understand the pattern of diagnosis, tumor characteristics and treatment. Material and methods. Between 1996 and 2005, all new cases of adenocarcinoma of the prostate gland were intended to be registered in the National Prostate Cancer Register (NPCR). This register contains information on diagnosing unit, date of diagnosis, cause of diagnosis, tumor grade, tumor stage according to the TNM classification in force, serum prostate-specific antigen (PSA) levels at diagnosis and primary treatment given within the first 6 months after diagnosis. Results. In total, 72 028 patients were registered, comprising >97% of all pertinent incident cases of prostate cancer in the Swedish Cancer Register (SCR). During the study period there was a considerable decrease in median age at the time of diagnosis, a stage migration towards smaller tumors, a decrease in median serum PSA values at diagnosis, a decrease in the age-standardized incidence rate of men diagnosed with distant metastases or with a PSA level of >100 ng/ml at diagnosis and an increase in the proportion of tumors with Gleason score ≤6. Relatively large geographical differences in the median age at diagnosis and the age-standardized incidence of cases with category T1c tumors were observed. Treatment with curative intent increased dramatically and treatment patterns varied according to geographical region. In men with localized tumors and a PSA level of <20 ng/ml at diagnosis, expectant treatment was more commonly used in those aged ≥75 years than in those aged <75 years. Also, the pattern of endocrine treatment varied in different parts of Sweden. Conclusions. All changes in the register seen over time are consistent with increased diagnostic activity, especially PSA testing, resulting in an increased number of cases with early disease, predominantly tumors in category T1c. The patterns of diagnosis and treatment of prostate cancer vary considerably in different parts of Sweden. The NPCR continues to be an important source for research, epidemiological surveillance of the incidence, diagnosis and treatment of prostate cancer [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
13. Prostate Cancer Radiation Therapy and Risk of Thromboembolic Events.
- Author
-
Bosco, Cecilia, Garmo, Hans, Adolfsson, Jan, Stattin, Pär, Holmberg, Lars, Nilsson, Per, Gunnlaugsson, Adalsteinn, Widmark, Anders, and Van Hemelrijck, Mieke
- Subjects
- *
PROSTATE cancer treatment , *CANCER radiotherapy , *THROMBOEMBOLISM risk factors , *COMORBIDITY , *CANCER invasiveness , *ATTRIBUTION (Social psychology) , *LONGITUDINAL method , *CANCER relapse , *PROGNOSIS , *PROSTATE tumors , *RADIATION injuries , *RADIOISOTOPE brachytherapy , *RADIOTHERAPY , *THROMBOEMBOLISM , *TREATMENT effectiveness , *DISEASE incidence , *RETROSPECTIVE studies , *DIAGNOSIS , *PREVENTION - Abstract
Purpose: To investigate the risk of thromboembolic disease (TED) after radiation therapy (RT) with curative intent for prostate cancer (PCa).Patients and Methods: We identified all men who received RT as curative treatment (n=9410) and grouped according to external beam RT (EBRT) or brachytherapy (BT). By comparing with an age- and county-matched comparison cohort of PCa-free men (n=46,826), we investigated risk of TED after RT using Cox proportional hazard regression models. The model was adjusted for tumor characteristics, demographics, comorbidities, PCa treatments, and known risk factors of TED, such as recent surgery and disease progression.Results: Between 2006 and 2013, 6232 men with PCa received EBRT, and 3178 underwent BT. A statistically significant association was found between EBRT and BT and risk of pulmonary embolism in the crude analysis. However, upon adjusting for known TED risk factors these associations disappeared. No significant associations were found between BT or EBRT and deep venous thrombosis.Conclusion: Curative RT for prostate cancer using contemporary methodologies was not associated with an increased risk of TED. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
14. Prostate Cancer Death After Radiotherapy or Radical Prostatectomy: A Nationwide Population-based Observational Study.
- Author
-
Robinson, David, Garmo, Hans, Lissbrant, Ingela Franck, Widmark, Anders, Pettersson, Andreas, Gunnlaugsson, Adalsteinn, Adolfsson, Jan, Bratt, Ola, Nilsson, Per, and Stattin, Pär
- Subjects
- *
RADIOTHERAPY complications , *CANCER-related mortality , *PROSTATE cancer patients , *PROSTATE cancer treatment ,PROSTATECTOMY complications - Published
- 2018
- Full Text
- View/download PDF
15. Gonadotropin-releasing Hormone Agonists, Orchiectomy, and Risk of Cardiovascular Disease: Semi-ecologic, Nationwide, Population-based Study.
- Author
-
Thomsen, Frederik Birkebæk, Sandin, Fredrik, Garmo, Hans, Lissbrant, Ingela Franck, Ahlgren, Göran, Van Hemelrijck, Mieke, Adolfsson, Jan, Robinson, David, and Stattin, Pär
- Subjects
- *
PROSTATE cancer treatment , *GONADOTROPIN releasing hormone , *CARDIOVASCULAR diseases risk factors , *CASTRATION , *ANDROGEN drugs - Abstract
Background In observational studies, men with prostate cancer treated with gonadotropin-releasing hormone (GnRH) agonists had a higher risk of cardiovascular disease (CVD) compared to men who had undergone orchiectomy. However, selection bias may have influenced the difference in risk. Objective To investigate the association of type of androgen deprivation therapy (ADT) with risk of CVD while minimising selection bias. Design, setting, and participants Semi-ecologic study of 6556 men who received GnRH agonists and 3330 men who underwent orchiectomy as primary treatment during 1992–1999 in the Prostate Cancer Database Sweden 3.0. Outcome measurements and statistical analysis We measured the proportion of men who received GnRH agonists as primary treatment in 580 experimental units defined by healthcare provider, diagnostic time period, and age at diagnosis. Incident or fatal CVD events in units with high and units with low use of GnRH agonists were compared. Net and crude probabilities were also analysed. Results and limitations The risk of CVD was similar between units with the highest and units with the lowest proportion of GnRH agonist use (relative risk 1.01, 95% confidence interval [CI] 0.93–1.11). Accordingly, there was no difference in the net probability of CVD after GnRH agonist compared to orchiectomy (hazard ratio 1.02, 95% CI 0.96–1.09). The 10-yr crude probability of CVD was 0.56 (95% CI 0.55–0.57) for men on GnRH agonists and 0.52 (95% CI 0.50–0.54) for men treated with orchiectomy. The main limitation was the nonrandom allocation to treatment, with younger men with lower comorbidity and less advanced cancer more likely to receive GnRH agonists. Conclusion Our data do not support previous observations that GnRH agonists increase the risk of CVD in comparison to orchiectomy. Patient summary We found a similar risk of cardiovascular disease between medical and surgical treatment as androgen deprivation therapy for prostate cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
16. Quantifying the Transition from Active Surveillance to Watchful Waiting Among Men with Very Low-risk Prostate Cancer.
- Author
-
Van Hemelrijck, Mieke, Garmo, Hans, Lindhagen, Lars, Bratt, Ola, Stattin, Pär, and Adolfsson, Jan
- Subjects
- *
PROSTATE cancer patients , *WATCHFUL waiting , *LIFE expectancy , *PROSTATE cancer treatment , *MEDICAL registries - Abstract
Background Active surveillance (AS) is commonly used for men with low-risk prostate cancer (PCa). When life expectancy becomes too short for curative treatment to be beneficial, a change from AS to watchful waiting (WW) follows. Little is known about this change since it is rarely documented in medical records. Objective To model transition from AS to WW and how this is affected by age and comorbidity among men with very low-risk PCa. Design, setting, and participants National population-based healthcare registers were used for analysis. Outcome measurements and statistical analysis Using data on PCa characteristics, age, and comorbidity, a state transition model was created to estimate the probability of changes between predefined treatments to estimate transition from AS to WW. Results and limitations Our estimates indicate that 48% of men with very low-risk PCa starting AS eventually changed to WW over a life course. This proportion increased with age at time of AS initiation. Within 10 yr from start of AS, 10% of men aged 55 yr and 50% of men aged 70 yr with no comorbidity at initiation changed to WW. Our prevalence simulation suggests that the number of men on WW who were previously on AS will eventually stabilise after 30 yr. A limitation is the limited information from clinical follow-up visits (eg, repeat biopsies). Conclusions We estimated that changes from AS to WW become common among men with very low-risk PCa who are elderly. This potential change to WW should be discussed with men starting on AS. Moreover, our estimates may help in planning health care resources allocated to men on AS, as the transition to WW is associated with lower demands on outpatient resources. Patient summary Changes from active surveillance to watchful waiting will become more common among men with very low-risk prostate cancer. These observations suggest that patients need to be informed about this potential change before they start on active surveillance. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
17. Re: Adi J. Klil-Drori, Hui Yin, Vicky Tagalakis, Armen Aprikian, Laurent Azoulay. Androgen Deprivation Therapy for Prostate Cancer and Risk of Venous Thromboembolism. Eur Urol 2016;70:56–61.
- Author
-
Van Hemelrijck, Mieke, Garmo, Hans, Adolfsson, Jan, and Stattin, Pär
- Subjects
- *
PROSTATE cancer treatment , *THROMBOEMBOLISM risk factors - Published
- 2017
- Full Text
- View/download PDF
18. Quantifying Observational Evidence for Risk of Fatal and Nonfatal Cardiovascular Disease Following Androgen Deprivation Therapy for Prostate Cancer: A Meta-analysis.
- Author
-
Bosco, Cecilia, Bosnyak, Zsolt, Malmberg, Anders, Adolfsson, Jan, Keating, Nancy L., and Van Hemelrijck, Mieke
- Subjects
- *
PROSTATE cancer patients , *ANDROGEN drugs , *PROSTATE cancer treatment , *CARDIOVASCULAR diseases risk factors , *HEALTH risk assessment - Abstract
Context Whether androgen deprivation therapy (ADT) for men with prostate cancer (PCa) increases the risk of cardiovascular disease (CVD) remains controversial. Pooled analyses using data from randomised controlled trials suggest no increased risk of fatal CVD following ADT, but no pooled analyses exist for observational studies. Objective To perform a meta-analysis using observational data on ADT and risk of CVD events in men with PCa. Evidence acquisition PubMed and Embase were searched using predefined inclusion criteria to perform meta-analyses on associations between types of ADT and nonfatal and fatal CVD outcomes using information from observational studies. Random effects meta-analyses were conducted to estimate relative risks (RRs) and 95% confidence intervals (CIs). Evidence synthesis A total of eight observational studies were identified studying at least one type of ADT and a nonfatal or fatal CVD outcome. The RR for risk of any type of nonfatal CVD was 1.38 (95% CI, 1.29–1.48) for men with PCa on gonadotropin-releasing hormone (GnRH) agonists, compared with men not treated with ADT. When analysing nonfatal ischemic heart disease only, the RR was 1.39 (95% CI, 1.26–1.54). The associations between GnRH agonists and nonfatal or fatal myocardial infarction or stroke were even stronger: RR: 1.57 (95% CI, 1.26–1.94) and RR: 1.51 (95% CI, 1.24–1.84), respectively. The results for other types of ADT in relation to the risk of any nonfatal CVD were RR: 1.44 (95% CI, 1.28–1.62) for orchiectomy and RR: 1.21 (95% CI, 1.07–1.367) for antiandrogens. Conclusions Observational data show a consistent positive association between ADT and the risk of CVD. This finding supports the need for future randomised trials of PCa patients that include older patients and men with multiple comorbidities to better reflect the general population. Patient summary We investigated all the available data from observational studies on hormonal treatment for prostate cancer and its possible cardiovascular adverse effects. We found consistent evidence that this treatment may increase the risk of cardiovascular disease. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
19. Thromboembolic Events Following Surgery for Prostate Cancer
- Author
-
Van Hemelrijck, Mieke, Garmo, Hans, Holmberg, Lars, Bill-Axelson, Anna, Carlsson, Stefan, Akre, Olof, Stattin, Pär, and Adolfsson, Jan
- Subjects
- *
THROMBOEMBOLISM , *PROSTATE cancer & genetics , *PROSTATE cancer treatment , *PROSTATE surgery , *PREOPERATIVE risk factors , *UROLOGICAL surgery - Abstract
Abstract: Background: Prostate cancer (PCa) and surgery are both associated with increased risk of thromboembolic diseases (TED). Objective: We assessed risk of TED among men undergoing different types of urologic surgery. Design, setting, and participants: Using the Prostate Cancer Database Sweden (PCBaSe) Sweden, we identified all men (n =45 065) undergoing pelvic lymph node dissection (PLND), radical prostatectomy (RP) with or without PLND, orchiectomy due to PCa, or a transurethral resection of the prostate (TURP). We identified a comparison cohort from the population. Outcome measurements and statistical analysis: Main outcomes were deep venous thrombosis (DVT) and pulmonary embolism (PE) as primary diagnoses in the National Patient Register or Cause of Death Register (2002–2010). We calculated hazard ratios (HR) and 95% confidence intervals (CI) using multivariable Cox proportional hazards models. Results and limitations: All surgical procedures were associated with increased risk of TED; laparoscopic and open RP with a PLND were the most strongly associated with TED (HR for PE: 8.1 [95% CI, 2.9–23.0] and 7.8 [95% CI, 4.9–13], respectively). For surgery including a PLND, the risk increased during the second half of the first postoperative month. The HR for PE after TURP in men with PCa was 3.0 (95% CI, 1.8–5.1). Patients with a history of TED had a strongly increased risk of TED (HR for DVT: 4.5; 95% CI, 2.6–8.0). A limitation is lack of information on TED prophylaxis, but its use was standardized during the study period for RP and PLND. Other limitations are lack of information on extent of PLND and lifestyle factors. Conclusions: Surgeries for PCa, including TURP, are associated with hospitalization for TED. Patients with a history of TED and patients undergoing a PLND were at highest risk. The largest risk was observed from days 14 to 28 postoperatively. Thus, our results suggest that prophylactic measures may be beneficial during the first 4 wk in these patients. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
20. Results of Conservative Management of Clinically Localized Prostate Cancer.
- Author
-
Chodak, Gerald W., Thisted, Ronald A., Gerber, Glenn S., Johansson, Jan-Erik, Adolfsson, Jan, Jones, George W., Chisholm, Geoff D., Moskovitz, Boaz, Livne, Pinhas M., and Warner, John
- Subjects
- *
PROSTATE cancer treatment - Abstract
Background: The selection of treatment for patients with localized prostate cancer requires reliable information about the outcome of conservative management. Previous studies of this question are generally considered unreliable because they were uncontrolled and nonrandomized. Methods: We performed a pooled analysis of 828 case records from six nonrandomized studies, published since 1985, of men treated conservatively (with observation and delayed hormone therapy but no radical surgery or irradiation) for clinically localized prostate cancer. A Cox regression analysis was performed to determine which factors influenced survival among patients who did not die of causes other than prostate cancer (disease-specific survival). Kaplan-Meier curves for overall and metastasis-free survival among such patients were compared with use of the log-rank method and the Mantel-Haenszel test. Results: Factors that had a significant effect on disease-specific survival were grade 3 tumors (risk ratio, 10.04), residence in Israel (risk ratio, 2.48) or New York (risk ratio, 0.37), and age under 61 years (risk ratio, 0.32). Ten years after diagnosis, disease-specific survival (with data on men who died from causes other than prostate cancer censored) was 87 percent for men with grade 1 or 2 tumors and 34 percent for those with grade 3 tumors; metastasis-free survival among men who had not died of other causes was 81 percent for grade 1, 58 percent for grade 2, and 26 percent for grade 3 disease. These findings were not affected by the inclusion of men who had early-stage cancer, were older, had worse-than-average health, or underwent delayed radiation therapy or radical prostatectomy. Conclusions: The strategy of initial conservative management and delayed hormone therapy is a reasonable choice for some men with grade 1 or 2 clinically localized prostate cancer, particularly for those who have an average life expectancy of 10 years or less. New treatment strategies are needed for men with grade 3 prostate cancer. (N Engl J Med 1994;330:242-8.) [ABSTRACT FROM AUTHOR]
- Published
- 1994
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.